Drug intelligence / Profile preview

Shunaoxin

Development stage
Unknown
Lead developer
Tianjin Pharmaceutical Da Ren Tang Group
Modality
Small Molecules
Administration
Oral
01

Overview

Shunaoxin is a Traditional Chinese Medicine (TCM) formulation, most commonly administered as dripping pills, developed by the Sixth Chinese Medicine Factory of Tianjin Zhongxin Pharmaceutical Group (now Tianjin Pharmaceutical Da Ren Tang Group). It is composed of concentrated extracts from *Ligusticum chuanxiong* and *Lycium barbarum*. The medication is primarily indicated for the treatment of cerebrovascular conditions such as cerebral infarction, cerebral arteriosclerosis, and associated symptoms including headache, dizziness, and memory loss. Its therapeutic effects are attributed to its ability to improve cerebral microcirculation, inhibit platelet aggregation, and provide neuroprotection against ischemic injury. Bioactive components like ligustrazine and ferulic acid contribute to its vasodilatory and antioxidant properties.

Brand names
Shunaoxin
Other names
Shunaoxin DiwanShunaoxin Dripping Pills
02

Targets

CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on Shunaoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shunaoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call